China and Eurasia Forum Quarterly, Volume 6, No. 3 (2008) p. 101-128 © Central Asia-Caucasus Institute & Silk Road Studies Program
ISSN: 1653-4212
PLOS ONE | www.plosone.org
September 2014 | Volume 9 | Issue 9 | e103657
braz j infect dis. 2014;18(5):491–495
http://dx.doi.org/10.1016/j.bjid.2014.02.004
1413-8670/© 2014 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
PLOS ONE | DOI:10.1371/journal.pone.0144057 December 14, 2015
Zanoni BC, et al. BMJ Glob Health 2016;1:e000004. doi:10.1136/bmjgh-2015-000004
PLOS ONE | https://doi.org/10.1371/journal.pone.0196239 April 23, 2018
WHO and UNITAID
in collaboration with IMPAACT (International Maternal Pediatric Adolescent AIDS Clinical Trials) network, PENTA (Paediatric European Network for Treatment of AIDS) foundation and experts from the Paediatric Antiretroviral Working Group
Supplement Article
www.jaids.com J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018
BMJ,Dodd PJ, et al. Thorax 2017;72:559–575. doi:10.1136/thoraxjnl-2016-209421
The Open AIDS Journal, 2012, 6, 245-258
Southern African Journal of HIV Medicine
ISSN: (Online) 2078-6751, (Print) 1608-9693
http://www.sajhivmed.org.za
Published: 23 May 2018
Global AIDS Update 2018
Closing Gaps
Breaking Barriers
Righting injustices
Combler les écarts
Rompre les barrières
Réparer les injustices
Synthèse
ПРактИЧеское РукоВодстВо для соВместных меРоПРИятИй.
Putting Asia’s HIV response back on track
EClinicalMedicine 1 (2018) 21–27
https://doi.org/10.1016/j.eclinm.2018.06.005
2589-5370/© 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
EClinicalMedicine: journal homepage: https://www.jo...urnals.elsevier.com/ eclinicalmedicine
Research Paper
more
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more